Consensus document on the use of sacubitril/valsartan in patients with heart failure: Consejo Interamericano de Falla Cardiaca e Hipertensión Pulmonar (CIFACAH) of the Inter-American Society of Cardiology (IASC)

Mario Speranza, Departamento de Cardiología, Hospital Clínica Bíblica, San José, Costa Rica
Clara I. Saldarriaga-Giraldo, Servicio de Cardiología, Clínica CardioVID, Universidad de Antioquia. Antioquia, Colombia
Carlos E. Ramos, Departamento de Cardiología, Instituto Nacional Cardiopulmonar, Tegucigalpa, Honduras
Daniel Quesada, Departamento de Cardiología, Hospital San Vicente de Paul, Heredia, Costa Rica
Víctor Rossel, Departamento de Cardiología, Hospital del Salvador, Santiago, Chile; Facultad de Medicina, Universidad de Chile, Santiago
Jaime R. Ventura-Umanzor, Departamento de Cardiología, Instituto Salvadoreño del Seguro Social, San Salvador, El Salvador
Freddy Pow-Chon, Departamento de Cardiología, Hospital Luis Vernaza; Departamento de Cardiología, Universidad Espíritu Santo, Guayaquil, Ecuador
Walter Alarco, Departamento de Cardiología, Instituto Nacional Cardiovascular, Lima, Perú
Yolanda Figueroa, Departamento de Cardiología, Legacy Medical Center, Humacao, Puerto Rico
Antonio Magaña-Serrano, Hospital de Cardiología Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de México; Asociación Mexicana de Insuficiencia Cardiaca, Ciudad de México; Asociación Nacional de Cardiólogos de México, Ciudad de México; México
Juan E. Gómez-Mesa, Departamento de Cardiología, Fundación Valle de Lili, Cali, Colombia
David Rodríguez-García, Departamento de Cardiología, Hospital Herrera Llerandi, Guatemala

Heart failure (HF) is a significant event for public health. It has a prevalence between 1-2%, mortality rate between 7-17%, and hospitalization between 32-44%. This implies a risk to health and quality of life, but also great financial efforts for health systems. Sacubitril/valsartan is a medication recognized for its efficacy, and this consensus seeks to synthesize the available information regarding its use for the benefit of patients. This document consists of a description of the epidemiology of HF, pharmacology of the drug, clinical trials, use of the drug in cases with reduced ejection fraction, mildly reduced ejection fraction and preserved ejection fraction, available literature on HF guidelines, recommendations and conclusions.

Keywords: Heart failure. Sacubitril-valsartan. Consensus.